Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma Ltd. has called an extraordinary general meeting of shareholders for March 5, 2026, to be held at its Tel-Aviv offices. The notice states that only holders of record of ADSs at the close of business on January 23, 2026 are entitled to receive notice and vote.
The board of directors recommends that shareholders vote “FOR” the proposals described in the proxy materials. ADS holders are asked to return their proxies by the deadline on their proxy form, and shareholders may submit written position statements to the company by February 23, 2026.
If a quorum is not reached within half an hour of the scheduled time, the meeting will be adjourned to a later date as determined by the board. The notice and related documents will be available on RedHill’s website and on the SEC website.
RedHill Biopharma reports new preclinical in vivo data suggesting its investigational drug opaganib may help overcome resistance to venetoclax, a key therapy for Chronic Lymphocytic Leukemia (CLL). In a mouse model, adding opaganib, a potent sphingosine kinase 2 (SPHK2) inhibitor, to venetoclax reduced CLL cells (CD19⁺, CD5⁺) by 50% versus controls and lowered certain T cell populations and PD1 expression, indicating a potential role in mitigating resistance to BCL‑2 inhibition.
The company highlights opaganib as a first‑in‑class, orally administered, host‑directed agent with anticancer, antiviral and anti‑inflammatory activity, with a safety and tolerability profile demonstrated in more than 470 clinical and expanded access participants. Opaganib is being evaluated in a Phase 2 trial with darolutamide in advanced prostate cancer, holds FDA orphan designations in cholangiocarcinoma and neuroblastoma, and is backed by several U.S. government programs, including BARDA, across oncology, radiation injury and pandemic preparedness indications.
RedHill Biopharma Ltd. (RDHL) reports that on November 26, 2025 it filed a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (ADSs) that may be issued and sold under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on February 3, 2025. Each ADS represents 10,000 ordinary shares of RedHill, with a par value of NIS 0.01 per share.
The report also notes that legal opinions and related consents from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP are filed as exhibits, and that this Form 6-K is incorporated by reference into multiple existing RedHill registration statements on Forms S-8 and F-3.
RedHill Biopharma Ltd. is increasing the maximum aggregate amount of American Depositary Shares it may sell under its at-the-market offering agreement with H.C. Wainwright & Co. to $352,267. Each ADS represents ten thousand Ordinary Shares, and this new limit applies only to future sales under the existing Sales Agreement.
As of this supplement, the company’s public float under Form F-3 was valued at $11,448,803.52, based on 45,431,765,990 Ordinary Shares held by non-affiliates, which would be represented by 4,543,176 ADSs at a price of $2.52 per ADS as of October 1, 2025. Over the prior 12 months, RedHill sold 890,001 ADSs via the program for approximately $3.4 million in gross proceeds, and any further increases in sale capacity will require an additional prospectus supplement.
RedHill Biopharma reported a legal milestone: the New York Supreme Court’s summary judgment in its favor against Kukbo is now final and eligible for enforcement and foreign recognition, with no further appeal permissible following expiry of the appeal period.
The Court awarded more than $10.5 million, comprising a main judgment of approximately $8.6 million, which is final and enforceable, and approximately $1.9 million for legal fees and expenses, which remains subject to appeal until March 13, 2026. Statutory interest of 9% per year continues to accrue on both awards. RedHill also obtained a Korean court attachment grant aimed at preventing Kukbo from disposing of assets prior to enforcement.
RedHill Biopharma reported receipt of a Nasdaq Staff Determination for continued non-compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). The company notes the minimum threshold is $2.5 million and says that, following its transaction with Cumberland Pharmaceuticals announced October 20, 2025, it believes equity now exceeds that level.
RedHill intends to appeal to a Nasdaq Listing Qualifications Panel, which may determine that compliance has been regained or grant up to a 180-day extension. Submission of a hearing request will stay any delisting or suspension action, and RedHill’s American Depositary Shares remain listed and traded on the Nasdaq Capital Market pending the Panel’s decision. The company cautions there is no assurance of a favorable outcome or an extension.
RedHill Biopharma Ltd. filed a prospectus supplement for the resale, from time to time, of up to 4,582,582 American Depositary Shares (ADSs), each representing 10,000 ordinary shares. The registration covers ADSs that may be issued to Alumni Capital LP under an Any Market Purchase Agreement establishing a committed equity line, including up to 333,333 ADSs issuable upon exercise of an unregistered commitment warrant.
The supplement also discloses a Letter Agreement dated October 20, 2025, which increases the beneficial ownership limitation for purchases made via Forward Purchase Notices from 4.99% to 9.99%. Purchases via Regular Purchase Notices remain capped at 4.99%. These limits prevent directing purchases that would result in Alumni and its affiliates exceeding the specified ownership thresholds at any single point in time.
RedHill Biopharma (RDHL) amended its Any Market Purchase Agreement with Alumni Capital to raise the beneficial ownership cap tied to Forward Purchase Notices from 4.99% to 9.99%. The agreement, originally signed on June 20, 2025, allows RedHill to sell up to $10,000,000 of ADSs to Alumni from time to time, at the company’s discretion.
Under a Forward Purchase Notice, Alumni may buy ADSs equal to the lesser of $500,000 or 30% of trading volume on the notice date, priced at the day’s lowest traded price multiplied by 96%. Other purchase types remain subject to a 4.99% ownership cap, with the option for the company to issue prefunded warrants instead of ADSs for Initial or Regular Purchase Notices. The amendment applies only to Forward Purchase Notices and does not change the overall program size.
RedHill Biopharma Ltd. announced a press release included in a Form 6-K describing a new ex‑US licensing deal for its H. pylori therapy Talicia and outlining the drug portfolio and public-health context for H. pylori treatment. The company states a new Middle East agreement includes upfront and milestone payments plus sales royalties totaling approximately $1.8M plus royalties. The release highlights Talicia as the leading branded H. pylori therapy among U.S. gastroenterologists, patent protection through 2042, and 8 years of U.S. market exclusivity under QIDP designation.
The filing summarizes H. pylori prevalence and risks: ~35 of U.S. adults (~1.6M treated annually), >50 globally, and up to ~80 in parts of the Middle East; H. pylori is linked to ~800,000 global deaths annually and ~27,000 U.S. gastric cancer diagnoses per year. The release notes rising antibiotic resistance and that current therapies fail in roughly 25-40 of patients, supporting the need for Talicia's rifabutin‑based regimen. The document also lists other pipeline assets and standard forward‑looking statements.
RedHill Biopharma Ltd. filed a Form 6-K attaching a press release that reports a New York Supreme Court appeal decision upholding a $10 million summary judgment in the company’s favor against Kukbo. The filing reiterates RedHill’s corporate registration details and lists recent and prior registration statements incorporated by reference. The document also summarizes RedHill’s clinical-stage pipeline, including opaganib (ABC294640) (multiple indications including GI-ARS, hospitalized COVID-19, prostate cancer), RHB-204 (planned Phase 2 for Crohn’s disease; Phase 3-stage for pulmonary NTM), RHB-107 (upamostat) (late-stage for non-hospitalized COVID-19 and other indications), and RHB-102 (positive Phase 2/3 results for GI indications; partnered with Hyloris Pharma). The filing contains no financial results or quantified impact of the judgment.